Top Biotech Stocks Over 1% Dividend Yield: Gilead Sciences Inc. (NASDAQ:GILD), Amgen Inc. (NASDAQ:AMGN), PDL BioPharma, Inc. (NASDAQ:PDLI), Theravance (NASDAQ:THRX), Grifols (NASDAQ:GRFS)

Gilead Sciences Inc. (NASDAQ:GILD) belongs to Healthcare sector. Its net profit margin is 51.70% and weekly performance is -1.13%. On last trading day company shares ended up $113.74. Gilead Sciences Inc. (NASDAQ:GILD) distance from 50-day simple moving average (SMA50) is 1.09%. On 1st July, Gilead Sciences, Inc. (NASDAQ:GILD) announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for an investigational, once-daily single tablet regimen that combines Gilead’s emtricitabine 200 mg and tenofovir alafenamide (TAF) 25 mg with rilpivirine 25 mg (R/F/TAF) from Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for the treatment of HIV-1 infection in adult and pediatric patients 12 years of age and older.

Amgen Inc. (NASDAQ:AMGN) shares advanced 1.84% in last trading session and ended the day at $154.10. AMGN Gross Margin is 80.70% and its return on assets is 8.20%. Amgen Inc. (NASDAQ:AMGN) quarterly performance is -5.22%. On 22 June it was reported Amgen Inc. (NASDAQ:AMGN) presented encouraging 52-week interim results from the open-label extension phase II study on AMG 334, which is being evaluated for the prevention of episodic migraine. Data were presented at the annual meeting of the American Headache Society (AHS).

On 10 July, PDL BioPharma, Inc. (NASDAQ:PDLI) shares advanced 4.13% and was closed at $6.30. PDLI EPS growth in last 5 year was 11.70%. PDL BioPharma, Inc. (NASDAQ:PDLI) year to date (YTD) performance is -14.58%. On 29 June, PDL BioPharma, Inc. (NASDAQ: PDLI) announced that it has entered into a credit agreement with CareView Communications, Inc. (OTCQB: CRVW) whereby PDL will provide CareView with up to $40 million of secured debt financing. CareView is an information technology provider to the healthcare industry focused on patient care monitoring.

Theravance Inc. (NASDAQ:THRX) ended the last trading day at $16.24. Company weekly volatility is calculated as 5.57% and price to cash ratio as 7.56. Theravance Inc. (NASDAQ:THRX) showed a weekly performance of -3.73%.

Grifols, S.A. (NASDAQ:GRFS) shares advanced 1.53% in last trading session and ended the day at $31.28. Grifols, S.A. (NASDAQ:GRFS) quarterly performance is -8.61%.Grifols SA, Barcelona (NASDAQ:GRFS) has been given a “BB+” credit rating by analysts at Morningstar. The firm’s “BB+” rating indicates that the company is an above-average default risk. They also gave their stock a four star rating.

Leave a Reply

Your email address will not be published. Required fields are marked *